CUPAB study
- Conditions
- Mild cognitive impairment, Alzheimer's Disease (AD) , non- AD, Cognitively unimpaired individuals
- Registration Number
- JPRN-jRCTs032200043
- Lead Sponsor
- akamura Akinori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 200
Cognitively unimpaired individuals;
1) Written informed consent is obtained.
2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study.
Mild cognitive impairment, Alzheimer's Disease (AD) , non- AD;
1) Written informed consent is obtained.The subject's legally acceptable representative must provide the written informed consent form if the subject is unable to provide informed consent.
2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study.
3) Diagnosed with any of the following diseases at informed consent.
Mild cognitive impairment
Alzheimer's Disease (AD)
non- AD
Cognitively unimpaired individuals;
1) GDS (Geriatric depression scale) > 6
2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint.
3) Having contraindications for MRI scans.
Mild cognitive impairment, AD , non- AD;
1) GDS > 11
2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint.
3) Having contraindications for MRI scans.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy of the plasma Amyloid beta biomarker to predict presence or absence of abnormal Amyloid beta deposition in the brain.
- Secondary Outcome Measures
Name Time Method 1) Sensitivity of the plasma Amyloid beta biomarker.<br>2) Specificity of the plasma Amyloid beta biomarker.<br>3) Probability of adverse events.